The Pharmacy Times® Chronic Obstructive Pulmonary Disease (COPD) resource center provides clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.
What can we help you find?
Results from the safety and efficacy trial of revefenacin (REV) demonstrated that the drug had a safety profile similar to foremoterol (FOR). In addition, patients with COPD in the suboptimal peak inspiratory flow rate trial (sPIFR) showed lower weight, BMI, and lung function in comparison to patients with optimal peak inspiratory flow rate (oPIFR) in a second study.
Starting on October 21st, aclidinium bromide and formoterol fumarate (DUAKLIR PRESSAIR, Circassia) will be available for the maintenance treatment of patients with COPD.
A researcher at the Washington University School of Medicine in St.Louis has received close to $7.5 million in total funding for research towards development of stem cell-based treatments for chronic pulmonary disease (COPD), asthma, and other disorders.
Researchers from John Hopkins Medicine have successfully used microscopic man-made particles to help predict early signs of severe chronic obstructive pulmonary disease (COPD) in patients.
The Phase III ETHOS trial for AstraZeneca's budesonide, glycopyrronium and formoterol fumarate, 320/14.4/9.6mcg (Breztri Aerosphere) combination therapy has demonstrated positive results for patients with moderate to severe chronic obstructive pulmonary disease (COPD).
Published in Clinical Rehabilitation, investigators found that breathing techniques commonly utilized in yoga may be an effective adjunct intervention for individuals with COPD.
A recent study found the prevalence of COPD was nearly 50% higher among patients with arthritis compared with those without arthritis, even after adjusting for sociodemographic characteristics, risk behaviors, frequent distress, and asthma status.
Interprofessional management of chronic obstructive pulmonary disease should include individualized approaches.
The combination treatment (Duaklir, Circassia) is designed to be administered twice-daily via AstraZeneca’s breath-actuated inhaler (Pressair).
The combination therapy was approved for twice-daily administration via the breath-actuated Pressair inhaler in patients with COPD.
Pharmacists have a great opportunity to educate patients about how to stay healthy and counsel those in need of symptom relief about their allergy treatment options.
Patients can breathe easier knowing that their local pharmacists are ideally positioned to help them manage their allegy, asthma and COPD conditions.
+ Load More